These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26560171)

  • 21. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in the clinical development of a dengue vaccine.
    Wallace D; Canouet V; Garbes P; Wartel TA
    Curr Opin Virol; 2013 Jun; 3(3):352-6. PubMed ID: 23747120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.
    Zellweger RM; Miller R; Eddy WE; White LJ; Johnston RE; Shresta S
    PLoS Pathog; 2013 Oct; 9(10):e1003723. PubMed ID: 24204271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mouse models of dengue virus infection for vaccine testing.
    Sarathy VV; Milligan GN; Bourne N; Barrett AD
    Vaccine; 2015 Dec; 33(50):7051-60. PubMed ID: 26478201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trials and tribulations on the path to developing a dengue vaccine.
    Thomas SJ; Rothman AL
    Vaccine; 2015 Nov; 33 Suppl 4():D24-31. PubMed ID: 26122583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response.
    Flipse J; Smit JM
    PLoS Negl Trop Dis; 2015; 9(6):e0003749. PubMed ID: 26065421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections.
    Kitab B; Kohara M; Tsukiyama-Kohara K
    Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress towards a dengue vaccine.
    Webster DP; Farrar J; Rowland-Jones S
    Lancet Infect Dis; 2009 Nov; 9(11):678-87. PubMed ID: 19850226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive immune responses to primary and secondary dengue virus infections.
    St John AL; Rathore APS
    Nat Rev Immunol; 2019 Apr; 19(4):218-230. PubMed ID: 30679808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current issues in dengue vaccination.
    Thomas SJ; Endy TP
    Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dengue infection and advances in dengue vaccines for children.
    Halstead SB; Dans LF
    Lancet Child Adolesc Health; 2019 Oct; 3(10):734-741. PubMed ID: 31378686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dengue vaccine candidates in development.
    Durbin AP; Whitehead SS
    Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dengue fever: theories of immunopathogenesis and challenges for vaccination.
    Remy MM
    Inflamm Allergy Drug Targets; 2014; 13(4):262-74. PubMed ID: 25163973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.
    Hughes HR; Crill WD; Davis BS; Chang GJ
    Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying protective dengue vaccines: guide to mastering an empirical process.
    Halstead SB
    Vaccine; 2013 Sep; 31(41):4501-7. PubMed ID: 23896423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.